Company Overview of Polyphor Ltd
Polyphor Ltd., a pharmaceutical company, engages in the discovery and development of macrocycle drugs addressing high unmet medical needs. Its product pipeline includes CXCR4 antagonist POL6326, a potent and selective antagonist of the chemokine receptor CXCR4 that blocks the interaction with the ligand stromal cell-derived factor 1 resulting in the mobilization of stem cells from the bone marrow into the circulating blood; Antibiotic POL7080, a pseudomonas specific antibiotic with a novel mode of action; and Neutrophil elastase inhibitor POL6014, a selective and reversible inhibitor of human neutrophil elastase for the treatment of respiratory diseases, such as chronic obstructive pulmonary...
Founded in 1996
Key Executives for Polyphor Ltd
Co-Founder and Chief Scientific Officer
Head of the Internal Services
Compensation as of Fiscal Year 2017.
Polyphor Ltd Key Developments
Polyphor Ltd Presents at Cambridge Healthtech Institute's 15th Annual Discovery on Target, Sep-25-2017 09:10 AM
Jun 13 17
Polyphor Ltd Presents at Cambridge Healthtech Institute's 15th Annual Discovery on Target, Sep-25-2017 09:10 AM. Venue: The Westin Copley Place, Boston, Massachusetts, United States. Speakers: Steffen Weinbrenner, Head of Drug Discovery.
Polyphor Names Kalina Scott as Chief Financial Officer, Effective from June 1St, 2017
May 23 17
Kalina Scott will join Polyphor as chief financial officer as of June 1st, 2017. She brings over 20 years of experience in the fields of mergers & acquisitions, capital markets and private placements in particular in the healthcare field, most recently as Managing Director, Corporate Finance with Bank am Bellevue in Zurich. Kalina started her career at UBS focusing on structured finance and credit risk management, followed by leading roles in UBS's investment banking in Zurich and London, covering leveraged finance as well as mergers & acquisitions, and in KPMG's Corporate Finance, where she built an IPO advisory unit.
Polyphor Presents Data for their Novel Class of Antibiotics
Apr 24 17
Polyphor presented promising data for their novel class of antibiotics, the Outer Membrane Protein Targeting Antibiotics (OMPTA). This is the first new class of antibiotic against Gram-negative pathogens to reach advanced clinical development in over 40 years. Murepavadin (POL7080), the first member of the OMPTA class currently in Phase II and soon expected to enter Phase III - is being developed for the treatment of the most severe Pseudomonas aeruginosa (PA) infection nosocomial pneumonia (including hospital-acquired and ventilator-associated pneumonia) - a disease with a death rate of 20%-50%. Early initiation of effective antimicrobial treatment for PA pulmonary infections is critical and a strong predictor of mortality. However, multi-drug resistant (MDR) PA has become a global problem and, as such, treatment is becoming more challenging with limited options available. Murepavadin, by means of its novel and unique mechanism of action, is extremely active and is being developed as first line treatment for MDR cases.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 12, 2017